These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 38837219)

  • 41. Results of the Italian infection-Carbapenem Resistance Evaluation Surveillance Trial (iCREST-IT): activity of ceftazidime/avibactam against Enterobacterales isolated from urine.
    Giani T; Antonelli A; Sennati S; Di Pilato V; Chiarelli A; Cannatelli A; Gatsch C; Luzzaro F; Spanu T; Stefani S; Rossolini GM
    J Antimicrob Chemother; 2020 Apr; 75(4):979-983. PubMed ID: 31958125
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Investigation of carbapenemases in carbapenem-resistant Escherichia coli and Klebsiella pneumoniae strains isolated in 2014 in Turkey].
    Çakar A; Akyön Y; Gür D; Karatuna O; Öğünç D; Özhak Baysan B; Çöplü N; Çağatay M; Kılıç A; Baysallar M; Bakıcı Z; Çelik C; Gülay Z; Aydemir Ş; Tünger A; Kılıç H; Erçal BD; Aşçı Toraman Z; Zer Y; Büyüktaş A; Ay S; Aktaş Z; Kayacan Ç; Bayramoğlu G; Aydın F; Dündar D; Hasdemir U; Ayaş R; Yanık K; Günaydın M; Güdücüoğlu H; Parlak M
    Mikrobiyol Bul; 2016 Jan; 50(1):21-33. PubMed ID: 27058326
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Acquisition of a Stable and Transferable
    Huang J; Zhang S; Zhao Z; Chen M; Cao Y; Li B
    Front Cell Infect Microbiol; 2021; 11():658070. PubMed ID: 34354959
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Identifying Spectra of Activity and Therapeutic Niches for Ceftazidime-Avibactam and Imipenem-Relebactam against Carbapenem-Resistant Enterobacteriaceae.
    Haidar G; Clancy CJ; Chen L; Samanta P; Shields RK; Kreiswirth BN; Nguyen MH
    Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28630202
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Mechanisms and fitness of ceftazidime/avibactam-resistant Klebsiella pneumoniae clinical strains in Taiwan.
    Chou SH; Chuang C; Juan CH; Ho YC; Liu SY; Chen L; Lin YT
    Int J Antimicrob Agents; 2024 Aug; 64(2):107244. PubMed ID: 38925227
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Klebsiella pneumoniae carbapenemase (KPC) producer resistant to ceftazidime-avibactam due to a deletion in the blaKPC3 gene.
    Antinori E; Unali I; Bertoncelli A; Mazzariol A
    Clin Microbiol Infect; 2020 Jul; 26(7):946.e1-946.e3. PubMed ID: 32061796
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Impact of Ceftazidime-Avibactam Treatment in the Emergence of Novel KPC Variants in the ST307-Klebsiella pneumoniae High-Risk Clone and Consequences for Their Routine Detection.
    Hernández-García M; Castillo-Polo JA; Cordero DG; Pérez-Viso B; García-Castillo M; Saez de la Fuente J; Morosini MI; Cantón R; Ruiz-Garbajosa P
    J Clin Microbiol; 2022 Mar; 60(3):e0224521. PubMed ID: 35107303
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Evolution of
    Won EJ; Park K; Jeong YS; Kim J; Choi Y; Kim SH; Kim MN; Sung H
    J Korean Med Sci; 2024 Jul; 39(25):e208. PubMed ID: 38952349
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Activity of ceftazidime-avibactam against carbapenemase-producing Enterobacteriaceae from urine specimens obtained during the infection-carbapenem resistance evaluation surveillance trial (iCREST) in Spain.
    García-Castillo M; García-Fernández S; Gómez-Gil R; Pitart C; Oviaño M; Gracia-Ahufinger I; Díaz-Regañón J; Tato M; Cantón R;
    Int J Antimicrob Agents; 2018 Mar; 51(3):511-515. PubMed ID: 29371104
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Ceftazidime/avibactam and eravacycline susceptibility of carbapenem-resistant Klebsiella pneumoniae in two Greek tertiary teaching hospitals.
    Chatzidimitriou M; Chatzivasileiou P; Sakellariou G; Kyriazidi M; Kavvada A; Chatzidimitriou D; Chatzopoulou F; Meletis G; Mavridou M; Rousis D; Katsifa E; Vagdatli E; Mitka S; Theodoros L
    Acta Microbiol Immunol Hung; 2021 Jun; 68(2):65-72. PubMed ID: 33522985
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Successive Emergence of Ceftazidime-Avibactam Resistance through Distinct Genomic Adaptations in
    Giddins MJ; Macesic N; Annavajhala MK; Stump S; Khan S; McConville TH; Mehta M; Gomez-Simmonds A; Uhlemann AC
    Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29263067
    [TBL] [Abstract][Full Text] [Related]  

  • 52. In vivo evolution of resistant subpopulations of KPC-producing Klebsiella pneumoniae during ceftazidime/avibactam treatment.
    Gaibani P; Campoli C; Lewis RE; Volpe SL; Scaltriti E; Giannella M; Pongolini S; Berlingeri A; Cristini F; Bartoletti M; Tedeschi S; Ambretti S
    J Antimicrob Chemother; 2018 Jun; 73(6):1525-1529. PubMed ID: 29566151
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Concomitant Resistance to Cefiderocol and Ceftazidime/Avibactam in Two Carbapenemase-Producing
    Bellinzona G; Merla C; Corbella M; Iskandar EN; Seminari E; Di Matteo A; Gaiarsa S; Petazzoni G; Sassera D; Baldanti F; Piazza A; Cambieri P
    Microb Drug Resist; 2024 Jan; 30(1):21-26. PubMed ID: 37870558
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Emergence of ceftazidime/avibactam resistance in KPC-3-producing Klebsiella pneumoniae in vivo.
    Göttig S; Frank D; Mungo E; Nolte A; Hogardt M; Besier S; Wichelhaus TA
    J Antimicrob Chemother; 2019 Nov; 74(11):3211-3216. PubMed ID: 31365094
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Impact of specific inhibitors on metallo-β-carbapenemases detected in Escherichia coli and Klebsiella pneumoniae isolates.
    Abbas HA; Kadry AA; Shaker GH; Goda RM
    Microb Pathog; 2019 Jul; 132():266-274. PubMed ID: 31096002
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Molecular Mechanisms Driving the
    Li X; Ke H; Wu W; Tu Y; Zhou H; Yu Y
    mSphere; 2021 Dec; 6(6):e0085921. PubMed ID: 34935448
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Minimum inhibitory concentrations of aztreonam-avibactam, ceftazidime-avibactam and meropenem in clinical isolates of Klebsiella pneumoniae harboring carbapenemase genes.
    Ageevets V; Sulian O; Avdeeva A; Chulkova P; Ageevets I; Gostev V; Alieva K; Golikova M; Sidorenko S
    J Antibiot (Tokyo); 2024 Oct; 77(10):706-710. PubMed ID: 38951709
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Emergence of ceftazidime-avibactam resistance due to a novel blaKPC-2 mutation during treatment of carbapenem-resistant Klebsiella pneumoniae infections.
    Liao Q; Deng J; Feng Y; Zhang W; Wu S; Liu Y; Che H; Xie Y
    J Infect Public Health; 2022 May; 15(5):545-549. PubMed ID: 35461077
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Reversion of KPC-114 to KPC-2 in ceftazidime-avibactam- resistant/meropenem-susceptible
    Pariona JGM; Vásquez-Ponce F; Becerra J; Martins-Gonçalves T; Pariona EMM; Madueño FT; Esposito F; V de Lima A; Mello Sampaio JL; Galhardo RS; Lincopan N
    Microbiol Spectr; 2024 Oct; 12(10):e0117324. PubMed ID: 39190636
    [No Abstract]   [Full Text] [Related]  

  • 60. Resistance to ceftazidime-avibactam in a KPC-2-producing Klebsiella pneumoniae caused by the extended-spectrum beta-lactamase VEB-25.
    Findlay J; Poirel L; Bouvier M; Gaia V; Nordmann P
    Eur J Clin Microbiol Infect Dis; 2023 May; 42(5):639-644. PubMed ID: 36877262
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.